Tactile Systems Technology, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Tactile Systems Technology, Inc.
Rona hopes technology acquired from Sanofi will enhance its RNA capabilities in liver and non-liver indications. NeuroFront gets Greater China and Singapore rights to Novaremed’s neuropathic pain drug.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Q3 medtech financing doubled in dollar volume to $3 billion, with debt offerings again representing the majority of the aggregate; acquisitions totaled $5.3 billion, mainly due to Johnson & Johnson’s $4.3 billion buy of Abbott Medical Optics. Diagnostics financings, which brought in $85 million, continued to decline, but at $5 billion, acquisitions showed a slight increase over the previous quarter, with Danaher’s takeover of Cepheid accounting for most of the M&A volume.
Q3 saw a rise in the volume of initial public offerings, sparking hopes for a potential IPO rebound in 2016.
- Medical Devices
- Other Names / Subsidiaries
- Tactile Medical
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.